Nasdaq
$0.6000▼ 0.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $43.4MShares out 72.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.14Pre-market26.10.14 06:35filed8-KKey event#●●●#●●●#●●●
Biomea Fusion, Inc.Bullish
Biomea Fusion announced topline results from its Phase 1 clinical trial of BMF-650, an investigational oral GLP-1 receptor agonist. The study demonstrated consistent weight reduction and favorable tolerability over four weeks, confirming the safety of a rapid one-step titration to a 400mg dose. The company plans to conduct further toxicology studies while seeking strategic partnerships and licensing arrangements for late-stage development.…more
$0.6000-0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22After-hours26.09.23 05:07424B5Offering
Biomea Fusion, Inc.
Biomea Fusion is conducting an offering of common stock and pre-funded warrants to raise up to $300 million in total proceeds. Konik Capital Partners has been engaged as the underwriter, and the offered securities are immediately separable upon issuance.…more
$0.6000-0.02%vs prev closeView filingShare - 9.22After-hours26.09.23 05:018-KKey event
Biomea Fusion, Inc.
Biomea Fusion, Inc. announced that the topline results from its ongoing Phase I GLP-131 trial for BMF-650 in obese, healthy volunteers are now expected to be released in October 2026. This update provides a revised timeline for the disclosure of clinical data for the drug candidate.…more
$0.6000-0.02%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Overnight26.10.14 15:12Bullish#●●●#●●●
Biomea Fusion Shares Plunge 28% Following Phase 1 Obesity Drug Data
Biomea Fusion shares fell over 28% in after-hours trading after releasing Phase 1 results for its oral GLP-1 candidate, BMF-650. The company plans to conduct further long-term toxicology studies and pursue potential strategic partnerships for the program.…more
$0.6000-0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.13After-hours26.10.14 05:29
●●●●●●●● ●●●●● ●●●●●●
Biomea Fusion's Phase 1 trial for its weight loss drug BMF-650 showed only mild to moderate adverse events, indicating a favorable safety profile. These findings remain preliminary based on four weeks of treatment, with further long-term trials and toxicology studies required.…more
$0.6000-0.02%vs prev closeShareBenzinga - 10.13After-hours26.10.14 05:08
●●●●●●●● ●●●●● ●●●●●●
Biomea Fusion announced positive Phase 1 results for its oral GLP-1 receptor agonist BMF-650, demonstrating consistent weight reduction and favorable tolerability. The company plans to seek strategic partnerships for further development, though additional long-term studies are required before commercialization.…more
$0.6000-0.02%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report